Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE:BAX) partners with AdventHealth Tampa to implement the Vital Edge program, expected to save the hospital approximately $200,000 annually. This program focuses on intraoperative hemostasis management, aiming to enhance clinical efficacy, operational efficiency, and financial performance. The initiative responds to growing concerns over surgical bleeding, which complicates patient outcomes and increases costs. Baxter's collaboration with AdventHealth aims to optimize the use of hemostatic agents, providing educational resources and data-driven insights for better hospital practices.

Baxter International Inc. (NYSE:BAX) announced a $50 million expansion of its sterile fill/finish manufacturing facilities in Bloomington, Indiana. This development, funded through Baxter and client investments, includes a new 25,000 sq. ft. warehouse, filling lines, and automated inspection lines. Construction is ongoing, with completion expected in 2021 and manufacturing set for 2022. The expansion will create approximately 100 new jobs at the site, enhancing Baxter's capabilities in sterile contract manufacturing for over 25 pharmaceutical companies.

Baxter International Inc. (NYSE:BAX) has received FDA clearance for its Homechoice Claria automated peritoneal dialysis (APD) system, featuring the Sharesource connectivity platform. This innovative system is designed for both adult and pediatric patients, enhancing remote patient management and promoting home dialysis growth. With over 6 million home dialysis treatments facilitated by Sharesource in the U.S., the new system aims to improve patient education and care efficiency. Homechoice Claria is slated for U.S. availability in the coming weeks.

Baxter International Inc. (NYSE:BAX) will participate in the Evercore ISI 3rd Annual HealthCONx virtual conference on December 1, 2020. Chief Financial Officer Jay Saccaro is set to present at 11:20 a.m. Eastern Time. The presentation will be available live via webcast at www.baxter.com and will remain accessible for replay until May 30, 2021. Baxter, a leader in medical products, supports millions of patients globally with critical care and surgical solutions, emphasizing innovative healthcare advancements for over 85 years.

Baxter International proposes to offer $650 million in senior notes due 2031, subject to market conditions. The offering targets qualified institutional buyers under Rule 144A and non-U.S. investors through Regulation S. The proceeds will be used to redeem $750 million of senior notes due 2025, which were issued in 2020. This strategic move aims to bolster Baxter’s balance sheet amidst market uncertainties. The notes won't be registered under the Securities Act initially and are offered privately. This press release does not constitute an offer to sell.

Baxter International Inc. (NYSE:BAX) reported third-quarter 2020 earnings with worldwide sales of $2.97 billion, a 4% increase year-over-year. U.S. sales totaled $1.2 billion, rising 2%, while international sales reached $1.7 billion, reflecting a 6% growth. Net income decreased 3% to $356 million, or $0.69 per diluted share, due to special items totaling $75 million. The company anticipates low single-digit sales growth for the full year and expects U.S. GAAP earnings between $2.41 and $2.44 per share. Baxter also emphasized its commitment to kidney health and corporate responsibility initiatives.

Baxter International (NYSE:BAX) acknowledges the results of a multicenter study from the OxirisNet Registry, focusing on COVID-19 patients treated with the Oxiris filter. The study indicated a significant reduction in serum IL-6 levels and improvements in organ function, correlating with a decrease in ICU mortality rates compared to historical controls. However, due to the study's observational design, no causal relationships can be established. The findings emphasize the potential of Oxiris in treating critically ill patients, paving the way for further research.

Baxter International Inc. (NYSE:BAX) supports findings from an ongoing study on critically ill COVID-19 patients, demonstrating the importance of indirect calorimetry in accurately assessing nutritional needs in ICU settings. The study, which analyzed 22 patients over 21 days, revealed that traditional predictive equations significantly understate patients' resting energy expenditure (REE). Notably, after the first week, average REE was 150% of predictions, with some cases reaching double. These findings underscore the risks associated with both over- and under-feeding in this vulnerable population.